Use of Kineret®
		Patients suffering from moderate to severely active rheumatoid arthritis (RA) may want to consider treatment with Kineret®. Kineret® has been shown to manage signs and symptoms and slow the progression of joint damage associated with RA in many sufferers who have not had success with disease-modifying antirheumatic drugs (DMARDs). It can be used alone or in combination with DMARDS, except for tumor necrosis factor (TNF) blocking agents, such as etanercept, infliximab, and adalimumab. Kineret® should not be used by anyone who has an infection that requires treatment with prescription antibiotics or that is serious enough to require treatment at a hospital. Kineret® should not be used by those with an allergy to proteins made from bacterial cells (E coli), or any of the ingredients in Kineret®, by anyone taking TNF blocking agents, such as Enbrel® (etanercept), or Remicade® (infliximab), or Humira® (adalimumab), unless a doctor has issued specific instructions to do so. When Kineret® is used with TNF blocking agents, such as Enbrel®, or Remicade®, or Humira®, it may increase the risk of a serious infection.   Enbrel® is a registered trademark of Immunex Corporation, Thousand Oaks, Ca. Remicade® is a registered trademark of Centocor, Inc., Malvern, Pa. Humira® is a registered trademark of Abbott Laboratories, Abbot Park, Il.   RHEUMATOID ARTHRITIS KINERET® AND RHEUMATOID ARTHRITIS DIET & EXERCISE REIMBURSEMENT IMPORTANT PRODUCT SAFETY INFORMATION
	Kineret® is a medicine that is used to reduce the pain and swelling associated with moderate to severe active rheumatoid arthritis. Kineret® is a man-made protein that is similar to a naturally occurring protein called interleukin-1 receptor antagonist (IL-1ra) found in the body. Kineret® is for use by patients eighteen years of age or older and for patients who have not responded to treatment with other agents called disease-modifying antirheumatic drugs or DMARDS. Kineret® can be used by itself or in combination with DMARDS. Kineret® should not be used with medicines called Tumor Necrosis Factor (TNF) blocking agents such as ENBREL® (etanercept), Humira™ (adalimumab), or Remicade® (infliximab). In clinical trials there was a risk of serious infections (2% in Kineret® patients vs. less than 1% in placebo patients). Kineret® should be discontinued if you develop an infection, however most often you can continue taking Kineret® after your infection resolves. You should not use Kineret® if you are taking TNF-blocking agents, such as etanercept, adalimumab, and infliximab, unless your doctor has told you to do so. If you use Kineret® with etanercept, adalimumab, or infliximab you may increase your risk of getting a serious infection. Kineret® should not be used if you know you are hypersensitive to E coli-derived proteins, Kineret®, or any ingredient of the product. The most common side effect in clinical trials was a reaction at the site of injection, which was usually mild and characterized by redness, swelling, and pain. Amgen.com | Site Map © 2008 Amgen. All rights reserved. This site is intended for U.S. audiences only.